Thus, this essential role of ZMYND8 in regulating the gene activator function of EZH2 might represent a viable target for the effective treatment of cancers under hypoxia or with VHL deficiency, such as ccRCC. This evidence concerns the gene EZH2 and nonpapillary renal cell carcinoma.